University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Pamela Munster, MD

Pamela Munster, MD

Professor, Department of Medicine (Hematology/Oncology), UCSF; Director, Early Phase Clinical Trials Unit, Co-leader of the Center for BRCA Research, and Leader, Experimental Therapeutics Program, UCSF Helen Diller Family Comprehensive Cancer Center

Cancer Center Program Memberships

Experimental Therapeutics | Cancer Genetics

Research Summary

My clinical research interests are first-in-human early phase clinical trials of novel compounds and alternative strategies for the treatment and prevention of cancer. I have been involved in clinical and translational research in early phase clinical trials since 1998. As the program leader for Development Therapeutics and the PI of a peer-reviewed basic science lab, my main focus is on translating preclinical findings into early-stage clinical trials with extensive PK and integration of PD correlative studies and molecular imaging for patients with advanced stage cancer.

My basic research interest is centered on the role of epigenetic modification in therapy resistance in breast cancer and epigenetic priming. In addition to studying basic mechanisms of hormone therapy resistance, we have shown that epigenetic modification plays a crucial role in the hormonal regulation and carcinogenesis of breast cancer.

Education

Kantonsschule Sargans, Switzerland, Baccalaureate, 1983, Sciences, Liberal Arts
University of Bern Switzerland, Doctorate, 1990, Medicine
University of Bern Switzerland, MD Thesis, 1992, Medicine


Professional Experience

  • 1990-1992
    University of Bern, Department of Physiology, Teaching Assignment in Physiology
  • 1992-1993
    Indiana University at Indianapolis, Krannert Institute of Cardiology
  • 1993-1996
    Residency in Internal Medicine Indiana University Medical Center at Indianapolis
  • 1996-1999
    Hematology-Oncology Fellowship at Memorial Sloan Kettering Cancer Center/The New York Hospital-Cornell Medical Center New York
  • 1999-2000
    Research Associate, Department of Medicine, Breast Program, Memorial Sloan Kettering Cancer Center, New York
  • 2000-2001
    Clinical Assistant Member, Memorial Sloan Kettering Cancer Center, Department of Medicine, Breast Cancer Service
  • 2001-2006
    Assistant Professor: Division of Breast Oncology & Experimental Therapeutics, Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center & Research Institute; Division of Medical Oncology & Hematology, Dept of Internal Medicine, University of South Florida
  • 2006-2008
    Associate Professor: Division of Breast Oncology & Experimental Therapeutics, Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center & Research Institute; Division of Medical Oncology & Hematology, Dept of Internal Medicine, University of South Florida
  • 2007-present
    Faculty Affiliate, Colorade State University, Ft. Collins, CO
  • 2008-2010
    Associate Professor in Residence, Department of Medicine, Division of Hematology/Oncology, UCSF
  • 2008-present
    Director, Early Phase Clinical Trials Program and Associate Director, Investigational Therapeutics, UCSF Helen Diller Family Comprehensive Cancer Center
  • 2010-present
    Professor in Residence, Department of Medicine, Division of Hematology/Oncology, UCSF

Honors & Awards

  • 1998
    John Mendelsohn House staff Teaching Award
  • 1999
    AACR-AFLAC Young Investigators Scholar Award 1999
  • 2000, 2001
    Byrne Fund Award
  • 2003-2005
    Don Shula Career Development Award, 2003-2005
  • 2007-2008
    Greatest Number of Investigator-Initiated Trials Written & Implemented, H. Lee Moffitt Cancer Center & Research Institute
  • 2008
    Research Highlights, Department of Defense, Congressionally Directed Medical Research Programs

Selected Publications

  1. Bartelink IH, Prideaux B, Krings G, Wilmes L, Lee PRE, Bo P, Hann B, Coppé JP, Heditsian D, Swigart-Brown L, Jones EF, Magnitsky S, Keizer RJ, de Vries N, Rosing H, Pawlowska N, Thomas S, Dhawan M, Aggarwal R, Munster PN, Esserman LJ, Ruan W, Wu AHB, Yee D, Dartois V, Savic RM, Wolf DM, van 't Veer L. Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors. Breast Cancer Res. 2017 Sep 11; 19(1):107.
    View on PubMed
  2. Thomas S, Chen S, Sbitany H, Kwon E, Piper M, Park J, Terranova Barberio M, Pawlowska N, Munster PN. Autologous Fat Grafting as a Novel Antiestrogen Vehicle for the Treatment of Breast Cancer. Plast Reconstr Surg. 2017 Sep; 140(3):537-544.
    View on PubMed
  3. Dhawan MS, Bartelink IH, Aggarwal R, Leng J, Zhang JZ, Pawlowska N, Terranova-Barberio M, Grabowsky JA, Gewitz A, Chien AJ, Moasser MM, Kelley RK, Maktabi T, Thomas S, Munster PN. Differential toxicity in patients with and without DNA repair mutations: Phase I Study of Carboplatin and Talazoparib in advanced solid tumors. Clin Cancer Res. 2017 Aug 08.
    View on PubMed
  4. Garrett SB, Koenig CJ, Trupin L, Hlubocky FJ, Daugherty CK, Reinert A, Munster P, Dohan D. What advanced cancer patients with limited treatment options know about clinical research: a qualitative study. Support Care Cancer. 2017 May 09.
    View on PubMed
  5. Martin T, Baz R, Benson DM, Lendvai N, Wolf J, Munster P, Lesokhin AM, Wack C, Charpentier E, Campana F, Vij R. A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. Blood. 2017 Jun 22; 129(25):3294-3303.
    View on PubMed
  6. Ott PA, Piha-Paul SA, Munster P, Pishvaian MJ, van Brummelen EMJ, Cohen RB, Gomez-Roca C, Ejadi S, Stein M, Chan E, Simonelli M, Morosky A, Saraf S, Emancipator K, Koshiji M, Bennouna J. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. Ann Oncol. 2017 05 01; 28(5):1036-1041.
    View on PubMed
  7. Tumeh PC, Hellmann MD, Hamid O, Tsai KK, Loo KL, Gubens MA, Rosenblum M, Harview CL, Taube JM, Handley N, Khurana N, Nosrati A, Krummel MF, Tucker A, Sosa EV, Sanchez PJ, Banayan N, Osorio JC, Nguyen-Kim DL, Chang J, Shintaku IP, Boasberg PD, Taylor EJ, Munster PN, Algazi AP, Chmielowski B, Dummer R, Grogan TR, Elashoff D, Hwang J, Goldinger SM, Garon EB, Pierce RH, Daud A. Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC. Cancer Immunol Res. 2017 May; 5(5):417-424.
    View on PubMed
  8. Guglin M, Munster P, Fink A, Krischer J. Lisinopril or Coreg CR in reducing cardiotoxicity in women with breast cancer receiving trastuzumab: A rationale and design of a randomized clinical trial. Am Heart J. 2017 Jun; 188:87-92.
    View on PubMed
  9. Block TS, Murphy TI, Munster PN, Nguyen DP, Lynch FJ. Glucocorticoid receptor expression in 20 solid tumor types using immunohistochemistry assay. Cancer Manag Res. 2017; 9:65-72.
    View on PubMed
  10. Aggarwal R, Thomas S, Pawlowska N, Bartelink I, Grabowsky J, Jahan T, Cripps A, Harb A, Leng J, Reinert A, Mastroserio I, Truong TG, Ryan CJ, Munster PN. Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies. J Clin Oncol. 2017 Apr 10; 35(11):1231-1239.
    View on PubMed
  11. Ferrarotto R, Mitani Y, Diao L, Guijarro I, Wang J, Zweidler-McKay P, Bell D, William WN, Glisson BS, Wick MJ, Kapoun AM, Patnaik A, Eckhardt G, Munster P, Faoro L, Dupont J, Lee JJ, Futreal A, El-Naggar AK, Heymach JV. Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors. J Clin Oncol. 2017 Jan 20; 35(3):352-360.
    View on PubMed
  12. Munster PN. Effect of Temporary Ovarian Suppression on Chemotherapy-Induced Amenorrhea, Pregnancy, and Outcome. JAMA Oncol. 2016 08 01; 2(8):1089-90.
    View on PubMed
  13. Dunn LB, Wiley J, Garrett S, Hlubocky F, Daugherty C, Trupin L, Munster P, Dohan D. Interest in Initiating an Early Phase Clinical Trial: Results of a Longitudinal Study of Advanced Cancer Patients. Psychooncology. 2016 May 27.
    View on PubMed
  14. Thomas S, Aggarwal R, Jahan T, Ryan C, Troung T, Cripps AM, Raha P, Thurn KT, Chen S, Grabowsky JA, Park J, Hwang J, Daud A, Munster PN. A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma. Ann Oncol. 2016 May; 27(5):947-52.
    View on PubMed
  15. Chien AJ, Cockerill A, Fancourt C, Schmidt E, Moasser MM, Rugo HS, Melisko ME, Ko AH, Kelley RK, Korn WM, Esserman LJ, van't Veer L, Yau C, Wolf DM, Munster PN. A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies. Breast Cancer Res Treat. 2016 Feb; 155(3):521-30.
    View on PubMed
  16. Rodriguez-Wallberg K, Turan V, Munster P, Oktay K. Can ovarian suppression with gonadotropin-releasing hormone analogs (GnRHa) preserve fertility in cancer patients? Ann Oncol. 2016 Feb; 27(2):357.
    View on PubMed
  17. Munster P, Aggarwal R, Hong D, Schellens JH, van der Noll R, Specht J, Witteveen PO, Werner TL, Dees EC, Bergsland E, Agarwal N, Kleha JF, Durante M, Adams L, Smith DA, Lampkin TA, Morris SR, Kurzrock R. First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies. Clin Cancer Res. 2016 Apr 15; 22(8):1932-9.
    View on PubMed
  18. Chien AJ, Duralde E, Hwang R, Tsung K, Kao CN, Rugo HS, Melisko ME, Esserman LJ, Munster PN, Cedars M, Kerlikowske K, McCulloch CE, Rosen MP. Association of tamoxifen use and ovarian function in patients with invasive or pre-invasive breast cancer. Breast Cancer Res Treat. 2015 Aug; 153(1):173-81.
    View on PubMed
  19. Piha-Paul SA, Munster PN, Hollebecque A, Argilés G, Dajani O, Cheng JD, Wang R, Swift A, Tosolini A, Gupta S. Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumours. Eur J Cancer. 2015 Sep; 51(14):1865-73.
    View on PubMed
  20. Gupta S, Argilés G, Munster PN, Hollebecque A, Dajani O, Cheng JD, Wang R, Swift A, Tosolini A, Piha-Paul SA. A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies. Clin Cancer Res. 2015 Dec 01; 21(23):5235-44.
    View on PubMed

Go to UCSF Profiles, powered by CTSI